Researchers have revealed that the use of Lynparza® to treat BRCA-mutated ovarian cancer results in a significant improvement in progression-free survival.
Browsing: Taxonomy > Biological and targeted therapies
Researchers have uncovered a key mechanism that drives hormone therapy resistance in prostate cancer.
A novel drug shows promise for preventing hearing loss in children after chemotherapy treatment for liver cancer.
Results from a Phase lll clinical trial demonstrate the success of a new targeted medicine, taselisib, in treating advanced breast cancer.
A prospective clinical trial, involving 100 men with metastatic castration-resistant prostate cancer, has demonstrated that black men experience a greater and longer lasting response to the hormone treatment abiraterone compared with white men.
In this article from CNS Oncology discover two case reports of adenocarcinoma and breast carcinoma that metastasized into an intracranial meningioma.
In this review article find out which treatment plan is most appropriate for different groups of acute lymphoblastic leukemia patients.
Researchers have reported that children with incurable brain tumors could benefit from a potentially life-extending treatment, if genetic testing is utilized to personalize their therapy. This personalized treatment has previously only been used in adults.
A team of researchers have identified the cause of resistance to breakthrough breast and ovarian cancer drugs.
A novel treatment strategy could overcome drug resistance in testicular cancer, find out exclusive details in this interview with study leader Janet Shipley from the ICR (London, UK).